

# North Carolina Medicaid Special Bulletin



An Information Service of the  
Division of Medical Assistance

Visit DMA on the Web at <http://www.ncdhhs.gov/dma>

**February 2018**

---

**Attention:  
All Providers**

**Generic Dispensing Rate Adjustments  
and  
Flovent HFA Inhaler Moved to Preferred Status on the  
Preferred Drug List**

## Flovent HFA Inhaler Moved to Preferred Status on the Preferred Drug List

Effective Feb. 3, 2017, Flovent HFA Inhaler has been moved to preferred status on the North Carolina Medicaid and NC Health Choice (NCHC) Preferred Drug List (PDL). This change is being made since Teva Pharmaceuticals has discontinued sales of QVAR Inhaler and to allow providers another preferred inhaled corticosteroid option.

Teva is replacing QVAR Inhaler with QVAR RediHaler, which is non-preferred. Patients and caregivers are encouraged to speak with a healthcare professional about how this transition may impact their current treatment plan.

<b>CORTICOSTEROIDS</b> <b>Clinical Criteria Apply</b>	
<b>Preferred</b>	<b>Non-Preferred</b>
Pulmicort Respules 0.25mg, 0.5mg, 1mg	Aerospan Inhaler
QVAR Inhaler	Alvesco Inhaler
<b>Flovent HFA Inhaler</b>	Arnuity Elipta Inhaler
	Asmanex HFA Inhaler
	Asmanex Twisthaler
	budesonide suspension (generic for Pulmicort Respules)
	Flovent Diskus / <del>HFA Inhaler</del>
	Pulmicort Flexhaler
	QVAR RediHaler

## Generic Dispensing Rate Adjustments

Generic dispensing rate adjustments go into effect on Feb. 1, 2018. These rates are based on the [Generic Dispensing Rate Report](#) for fourth quarter 2017.

---

**Sandra Terrell, MS, RN**  
**Director of Clinical**  
**Division of Medical Assistance**  
**Department of Health and Human Services**

---

**Paul Guthery**  
**Executive Account Director**  
**CSRA**